{"title":"谁付吹笛者","authors":"M. Thornton","doi":"10.1002/9781444395372.CH7","DOIUrl":null,"url":null,"abstract":"The decision of the federal government in Australia not to accept the Pharmaceutical Benefits Advisory Committee's (PBAC) recommendation for new medicines and vaccines to be included in the Pharmaceutical Benefits Scheme (PBS) is discussed. The reasons for the controversial decision of the government are being debated.","PeriodicalId":125025,"journal":{"name":"The Australian Pharmacist","volume":"89 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"He Who Pays the Piper\",\"authors\":\"M. Thornton\",\"doi\":\"10.1002/9781444395372.CH7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The decision of the federal government in Australia not to accept the Pharmaceutical Benefits Advisory Committee's (PBAC) recommendation for new medicines and vaccines to be included in the Pharmaceutical Benefits Scheme (PBS) is discussed. The reasons for the controversial decision of the government are being debated.\",\"PeriodicalId\":125025,\"journal\":{\"name\":\"The Australian Pharmacist\",\"volume\":\"89 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Australian Pharmacist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/9781444395372.CH7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Australian Pharmacist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/9781444395372.CH7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The decision of the federal government in Australia not to accept the Pharmaceutical Benefits Advisory Committee's (PBAC) recommendation for new medicines and vaccines to be included in the Pharmaceutical Benefits Scheme (PBS) is discussed. The reasons for the controversial decision of the government are being debated.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
